Key Background
The Patna High Court, presided by Justice Ashok Kumar Pandey, has identified a concerning pattern in the application of the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Particularly, the court noted the misuse of the Act in cases involving cough syrups with codeine, a common pharmaceutical compound. This observation arose while hearing a bail application connected to Mansi P.S. Case No. 218 of 2025. The case initially registered under Section 30(f) of the Bihar Prohibition and Excise Act was reclassified under Sections 8(c), 21(b), and 29 of the NDPS Act, suggesting a significant legal turn which the court found unjustified.
Core Legal Analysis
The prosecution indicated that over 1200 bottles of RTX-SCEN, a cough syrup with approximately 0.2% codeine concentration, were recovered. The petitioner argued wrongful framing, contending the lack of independent seizure witnesses, and emphasized that under Notification No. S.O. 826(E), such a composition is exempt from being classified as a narcotic drug if under 2.5% concentration.
Specific Provisions or Sections
This case hinged upon nuanced interpretations of the NDPS Act and the Drugs and Cosmetics Act, highlighting discrepancies in its application. Citing Notification No. S.O. 826(E) by the NDPS Act, the petitioner contended the inappropriateness of applying and asserting the serious implications of Section 2(d) in this context, which delineates what constitutes a narcotic drug.
Notable Cases or Precedents
The State took a contrasting stance, leveraging the Supreme Court decision in Hira Singh v. Union of India as a precedent to argue the inclusion of entire mixtures for determining quantity, thereby allegedly falling into the commercial category. However, the court established that the Central Government's guidelines allowed codeine concentrations below 2.5% to be exempted and thus, the question of quantity was moot under the NDPS Act parameters.
Ratio Decidendi and Obiter Dicta
In its rationale, the Patna High Court underscored the misalignment in framing charges for cases involving medically permissible codeine quantities under NDPS regulations instead of the Drugs and Cosmetics Act. The bench criticized this procedural misdirection, reaffirming that such instances ought not to be classified under criminal acts commonly associated with contraband handling.
Conclusion
The judgment by the Patna High Court in Sanjeev Kumar v. State of Bihar, signifies a pivotal shift in interpreting legal frameworks governing pharmaceutical products, emphasizing adherence to statutory exemptions. This ruling brings to attention the importance of precise statutory application, disallowing broad interpretations that could adversely affect legitimate pharmaceutical operations. Such cases highlight the necessity for practitioners to scrutinize statutory applicability before pursuing litigation under stringent drug regulations.
